




PC25937A-US

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA on this 12th day of May, 2006

By

  
(Signature of person mailing)

Pamela C. Ancona, Ph.D.  
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIN RE APPLICATION OF: **Kath, et al.**: Examiner: **V. Balasubramanian**SERIAL NO.: **10/733,215**: Unit: **1624**FILED: **DECEMBER 11, 2003**FOR: **PYRIMIDINE COMPOUNDS FOR THE  
TREATMENT OF ABNORMAL CELL GROWTH**

Mail Stop Amendment  
Commissioner of Patents  
Alexandria, VA 22313-1450

Sir:

**TERMINAL DISCLAIMER**

Pfizer Inc. is the owner of 100% interest in the above-captioned application and in second application serial number 11/127,809, filed on May 12, 2005. Pfizer Inc. hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-captioned application, which would extend beyond the expiration date of the full statutory term of any patent issuing on said second application, including any patent term extensions, restorations or adjustments for said patent issuing on said second application available under all applicable statutes including 35 U.S.C. §§ 154 through 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent issuing on said second application. The owner hereby agrees that any patent so granted on the above-captioned application shall be enforceable only for and during such period that the legal title to it and to any patent issuing on said second application shall be commonly owned. This agreement runs with any patent granted on the above-captioned application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the above-captioned application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of any patent issuing on said second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that the patent issuing on said second application expires for failure to pay a maintenance fee, is held unenforceable and/or invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claimed canceled by a reexamination certificate, is reissued, or its term is in any manner shortened prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

This Terminal Disclaimer is accompanied by a Fee Transmittal Sheet authorizing payment of the appropriate fee under 37 C.F.R. § 1.20(d).


05/17/2006 FFANAEIA 00000005 161445 10733215

01 FC:1814 130.00 DA

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

Date: May 12, 2006

  
\_\_\_\_\_  
Pamela C. Ancona, Ph.D.  
Senior Corporate Counsel  
Reg. No. 41,494  
(212) 733-6031

Pfizer Inc.  
Patent Dept., 5th Fl.  
150 East 42nd Street  
New York, NY 10017-5755